By Professor Michael Leonard Friedlander

Conference Papers

Friedlander M; Gebski V; Gibbs E; Bloomfield R; Hilpert F; Wenzel LB; Joly F; Eek D; Rodrigues M; Clamp AR; Penson RT; Provencher DM; Korach J; Huzarski T; Vidal L; Salutari V; Scott CL; Nicoletto MO; Tamura K; Pujade-Lauraine E, 2017, 'Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5507

Ledermann JA; Embleton AC; Perren T; Jayson GC; Rustin GJS; Kaye SB; Hirte HW; Oza AM; Vaughan MM; Friedlander M; Martin AG; Clark E; Popoola B; Farrelly L; Swart AM; Cook A; Kaplan RS; Parmar MKB, 2017, 'Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5506

Grimison PS; Lawrence NJ; Stockier MR; Martin AJ; Yip S; Wong N; Yeung A; Friedlander M; Mazhar D; Pashankar F; Quinn DI; Walker R; Winstanley M; Nanning FJ; Weickhardt AJ; Stevanovic AG; Davis ID; Toner GC, 2017, 'P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.TPS4592

Roncolato F; Joly F; O'Connell R; Lanceley A; Heitz F; Buizen L; Okamoto A; Aotani E; Salutari V; Donnellan PP; Oza AM; AvalI-Lundqvist E; Berek JS; Hilpert F; Feeney A; Roemer-Becuwe C; Stockier MR; King MT; Friedlander M, 2017, 'Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had >= 3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5575

Heinzelmann-Schwarz VA; Russell K; Omar S; Schoetzau A; Hoeck K; Vetter M; Fink DA; Friedlander M; Hacker NF, 2017, 'Should MMMT of the endometrium/ovary be treated with anthracycline instead of taxane based chemotherapy?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5563

Piskorz A; Lin KK; Morris J; Mann E; Oza A; Coleman RL; O'Malley DM; Friedlander M; Cragun JM; Ma L; Giordano H; Rosenfeld N; Raponi M; McNeish IA; Swisher E; Brenton JD, 2017, 'Abstract AP27: FEASIBILITY OF MONITORING RESPONSE TO THE PARP INHIBITOR RUCAPARIB WITH TARGETED DEEP SEQUENCING OF CIRCULATING TUMOR DNA (CTDNA) IN WOMEN WITH HIGH GRADE OVARIAN CARCINOMA ON THE ARIEL2 TRIAL', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. AP27 - AP27, http://dx.doi.org/10.1158/1557-3265.ovcasymp16-ap27

Joly F; Hilpert F; Okamoto A; Stuart G; Ochiai K; Friedlander M, 2017, 'Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer', in European Journal of Cancer, pp. 133 - 138, http://dx.doi.org/10.1016/j.ejca.2017.03.019

Pujade-Lauraine E; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Friedlander M; Colombo N, 2017, 'Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 219 - 220, http://dx.doi.org/10.1016/j.ygyno.2017.03.505

Han HS; Dieras V; Robson ME; Palacova M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Man BK; Ratajczak C; Coates A; Bonnet P; Qin Q; Qian J; Giranda VL; Shepherd SP; Isakoff SJ; Puhalla S, 2016, 'Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 06 December 2016 - 10 December 2016, http://dx.doi.org/10.1158/1538-7445.SABCS16-S2-05

Dieras V; Han HS; Robson ME; Palacova M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Kaufman B; Ratajczak C; Coates A; Bonnet P; Qin Q; Qian J; Giranda VL; Shepherd SP; Puhalla S; Isakoff SJ, 2016, 'Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V plus TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 06 December 2016 - 10 December 2016, http://dx.doi.org/10.1158/1538-7445.SABCS16-P4-22-02

Piskorz AM; Lin KK; Morris J; Mann E; Oza A; Coleman RL; O'Malley DM; Friedlander M; Cragun JM; Ma L; Giordano H; Raponi M; McNeish IA; Swisher E; Brenton JD, 2016, 'Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade ovarian carcinoma on the ARIEL2 trial', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, GERMANY, Munich, pp. S123 - S123, presented at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, GERMANY, Munich, 29 November 2016 - 02 December 2016, http://dx.doi.org/10.1016/S0959-8049(16)32966-5

Hickey M; Sousa MS; Peate M; Jarvis S; Friedlander M, 2016, 'SHORT-TERM FINDINGS OF THE PEGASUS STUDY: GENITOURINARY SYMPTOMS, SEXUALITY AND QUALITY OF LIFE IN BREAST CANCER SURVIVORS ON ENDOCRINE THERAPY - WHAT ARE WE MISSING?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 71 - 71, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000387769900021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mercieca-Bebber R; Calvert MJ; Kok P-S; Friedlander M; Kyte DG; Stockler M; King M, 2016, 'Does the patient-reported outcome (PRO) content of protocols impact PRO completion rates and the standard of reporting? A review of international ovarian cancer randomized controlled trials (RCTs)', in QUALITY OF LIFE RESEARCH, SPRINGER, pp. 119 - 119, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398451600288&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wenzel L; King M; Lee C; Kirby A; Friedlander M; Hilpert F; Stockler M; Gelski V, 2016, 'Relationship between distress and survival in women with platinum-resistant ovarian cancer (PROC)', in QUALITY OF LIFE RESEARCH, SPRINGER, pp. 125 - 125, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398451600301&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lawrence N; Grimison P; Stockler M; Martin A; Buizen L; Thomson D; Gebski V; Friedlander M; Yeung A; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong S; Lewis C; Vasey P; Toner G, 2016, 'LONG-TERM OUTCOMES OF ACCELERATED BEP (BLEOMYCIN, ETOPOSIDE, CISPLATIN) FOR ADVANCED GERM CELL TUMORS: UPDATED ANALYSIS OF AN AUSTRALIAN MULTICENTER PHASE II TRIAL (3033)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 48 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000380005100014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lawrence N; Martin A; Toner G; Stockler M; Buizen L; Thomson D; Gebski V; Friedlander M; Yeung A; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong S; Lewis C; Vasey P; Grimison P, 2016, 'LONG-TERM OUTCOMES OF ACCELERATED BEP (BLEOMYCIN, ETOPOSIDE, CISPLATIN) FOR ADVANCED GERM-CELL TUMORS: UPDATED ANALYSIS OF AN AUSTRALIAN MULTICENTER PHASE II TRIAL', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 28 - 28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000380004900011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Desai J; Markman B; Sandhu SK; Gan HK; Friedlander M; Tran B; Meniawy T; Boolell V; Colyer D; Norris C; Ameratunga M; Yang J; Li K; Wang L; Luo L; Qin Z; Millward M, 2016, 'A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.3066

Roncolato F; O'Connell R; Buizen L; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan PP; Oza AM; Avall-Lundqvist E; Berek JS; Sjoquist KM; Gillies K; Stockler MR; King MT; Friedlander M, 2016, 'Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5508

Piskorz A; Lin KK; Morris JA; Mann E; Oza AM; Coleman RL; O'Malley DM; Friedlander M; Cragun JM; Ma L; Giordano H; Raponi M; McNeish IA; Swisher EM; Brenton JD, 2016, 'Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5549

Grimison PS; Stockler MR; Martin AJ; Buizen L; Lawrence NJ; Thomson DB; Gebski V; Friedlander M; Yeung A; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC, 2016, 'Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumors: updated analysis of an Australian multicenter phase II trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.e16056

Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin GJS; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei DE; Fielding A; Spencer S; Rowe P; Lowe ES; Matulonis UA, 2016, 'Overall survival (OS) in patients (pts) with platinum sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5501

Mileshkin LR; Edmondson RJ; O'Connell R; Sjoquist KM; Cannan D; Jyothirmayi R; Beale PJ; Bonaventura T; Goh JC; Hall M; Clamp AR; Green JA; Lord R; Scurry J; Friedlander M, 2016, 'Phase II study of anastrozole in recurrent estrogen (ER) / progesterone (PR) positive endometrial cancer: The PARAGON trial-ANZGOG 0903.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5520

Roncolato F; Gibbs E; Lee C; Davies LC; Gebski V; Friedlander M; Hilpert F; Wenzel LB; Stockler MR; King MT; Pujade-Lauraine E, 2016, 'Quality of life (QOL) to predict overall survival (OS) in women with platinum-resistant ovarian cancer (PROC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5575

Lee YC; Milne RL; Smith C; Picken S; Camm S; McLachlan S-A; Friedlander M; Hopper JL; Phillips K-A, 2016, 'Risk of uterine cancer in BRCA1 and BRCA2 mutation carriers.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.1529

Grunewald T; Tang M; Chen J; Lord S; Friedlander M; Lee CK, 2016, 'Where have we gone wrong? Phase II trials (Ph2t) do not inform the results of phase III trials (Ph3t) in platinum resistant ovarian cancer (PROC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5559

Hipert F; Friedlander M; Stockler M; O'Connell R; Joly F; Lanceley A; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Sjoquist K; Gillies K; Butow P; King M, 2016, 'Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving >= 3 lines of chemotherapy (PPS >= 3) - GCIG Symptom Benefit Study (AGO PRO1).', in ONCOLOGY RESEARCH AND TREATMENT, KARGER, pp. 138 - 139, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000371353700449&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lawrence N; Toner G; Martin A; Stockler M; Yeung A; Wong N; Thomson D; Gebski V; Yip S; King M; Friedlander M; Quinn D; Tan TH; Chan H; Hanning F; Weickhardt A; Jeffery M; Stevanovic A; Hovey E; Wyld D; Davis I; Grimison P, 2015, 'A RANDOMISED PHASE 3 TRIAL OF ACCELERATED VERSUS STANDARD BEP CHEMOTHERAPY FOR PATIENTS WITH INTERMEDIATE AND POOR-RISK METASTATIC GERM CELL TUMOURS: THE P3BEP TRIAL (ANZUP 1302)', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 146 - 147, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800237&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Roncolato F; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Sjoquist K; Gillies K; Butow P; Stockler M; King M; Friedlander M; Kok P-S, 2015, 'BASELINE PREDICTORS OF EARLY TREATMENT FAILURE IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY (PRR) AND POTENTIALLY PLATINUM SENSITIVE (PPS) RECURRENT OVARIAN CANCER (ROC) RECEIVING >= 3 LINES OF CHEMOTHERAPY- THE GYNAECOLOGIC CANCER INTERGROUP (GCIG) SYMPTOM BENEFIT STUDY (SBS)', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 125 - 125, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800179&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander M; Stockler M; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Sjoquist K; Gillies K; Butow P; King MT, 2015, 'IS IT TIME TO CHANGE THE PRIMARY ENDPOINT IN CLINICAL TRIALS IN RECURRENT OVARIAN CANCER (ROC)? SYMPTOM BURDEN AND OUTCOMES IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY (PRR) AND POTENTIALLY PLATINUM SENSITIVE ROC RECEIVING >= 3 LINES OF CHEMOTHERAPY (PPS) - THE GYNECOLOGIC CANCER INTERGROUP (GCIG) SYMPTOM BENEFIT STUDY (SBS)', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 111 - 111, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800146&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Beale P; O'Connell R; Sjoquist K; Martyn J; Cannon D; Bonaventura T; Grant P; Goh J; Antill Y; Friedlander M; Scurry J, 2015, 'PARAGON-AN ANZGOG PHASE 2 STUDY OF ANASTRAZOLE IN ASYMPTOMATIC WOMEN WITH ESTROGEN (ER)/PROGESTERONE (PR) POSITIVE OVARIAN CANCER WITH A CA125 PROGRESSION AFTER FIRST LINE TREATMENT', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 118 - 118, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800164&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

King M; Stockler M; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Buizen L; Sjoquist K; Butow P; Friedlander M; Gillies K; Martyn J, 2015, 'VALIDATION OF A PATIENT REPORTED OUTCOME MEASURE (PROM) OF OVARIAN CANCER SYMPTOMS AND TREATMENT RELATED CONCERNS (MOST-OSI) WITH CHEMOTHERAPY IN RECURRENT OVARIAN CANCER (ROC).', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 457 - 458, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000377145701081&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

King M; Stockler M; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Buizen L; Sjoquist K; Gillies K; Butow P; Friedlander M, 2015, 'Validation of the measure of ovarian symptoms and treatment concerns (MOST), a patient-reported outcome measure (PROM) of symptom burden and subjective benefit with chemotherapy in recurrent ovarian cancer (ROC)', in QUALITY OF LIFE RESEARCH, SPRINGER, pp. 22 - 23, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000361991100056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Huggins-Puhalla SL; Han HS; Dieras V; Friedlander M; Somlo G; Arun B; Wildiers H; Kaufman B; Ayoub J-PM; Shah M; Burmedi D; Qin Q; Qian J; Giranda VL; Shepherd SP, 2015, 'Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Breast Cancer Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 25 September 2015 - 27 September 2015, http://dx.doi.org/10.1200/jco.2015.33.28_suppl.155

Roncolato FT; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan PP; Oza AM; Avall-Lundqvist E; Berek JS; Sjoquist KM; Gillies K; Butow P; Stockler MR; King MT; Friedlander M, 2015, 'Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS >= 3) recurrent ovarian cancer (ROC) receiving >= 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5564

Lee C; Gibbs E; Roncolato FT; Davies LC; Le Maignan C; Meier W; Lanza MAA; Rosenberg P; Marchetti C; Vergote I; Witteveen P; Bamias A; Serra S; Provencal J; De Rauglaudre G; Gebski V; Friedlander M; Pujade-Lauraine E, 2015, 'Development and validation of a prognostic nomogram to predict overall survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA substudy.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5547

Phillips K-A; Collins IM; Milne RL; Fisher R; Stern C; Kannemeyer G; Smith C; Friedlander M; McLachlan S-A; Hickey M; Hopper JL, 2015, 'Do women with BRCA1 or BRCA2 mutations have reduced ovarian reserve?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.1537

Domchek SM; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmana J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Loman N; Robertson JD; Mann H; Kaufman B, 2015, 'Efficacy and safety of olaparib monotherapy in a subgroup of patients with a germline BRCA1/2 mutation and advanced ovarian cancer from a Phase II open-label study.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5529

Matulonis U; Friedlander M; Du Bois A; Gourley C; Vergote I; Rustin GJS; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; McMurtry E; Spencer S; Mann H; Parry D; Ledermann JA, 2015, 'Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5550

Friedlander M; Stockler MR; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan PP; Oza AM; Avall-Lundqvist E; Berek JS; Sjoquist KM; Gillies K; Butow P; King MT, 2015, 'Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: Symptom burden and outcomes in patients with platinum resistant/ refractory (PRR) and potentially platinum sensitive ROC receiving >= 3 lines of chemotherapy (PPS >= 3)-The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5536

Debernardo R; Mahdi H; Russell K; Xiu J; Millis SZ; Reddy SK; Friedlander M, 2015, 'Molecular profile comparison of endometrial, renal and ovarian clear cell carcinoma: Is it the same disease at different sites?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5595

Friedlander M; Russell K; Millis SZ; Gatalica Z; Voss A, 2015, 'Molecular profiling of mucinous epithelial ovarian carcinomas (mEOC): Opportunities for clinical trials.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5540

Puhalla S; Han HS; Dieras V; Friedlander M; Somlo G; Arun B; Wildiers H; Kaufman B; Ayoub J-PM; Shan M; Burmedi D; Qin Q; Qian J; Giranda VL; Shepherd SP, 2015, 'Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 51st Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps1102

Rafii S; Gourley C; Ang JE; Kumar R; Geuna E; Rye T; Ashcroft L; Powell B; Shapira-Frommer R; Friedlander M; Chen L-M; Matulonis U; Kaufman B; De Greve J; Oza AM; Banerjee SN; Gore ME; Molife LR; Kaye SB; Yap TA, 2015, 'What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5546

Segelov E, 2015, 'TOPS - a randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue', Chicago, presented at 2015 ASCO Annual Meeting, Chicago, 29 May 2015 - 02 June 2015

Matulonis UA; Harter P; Gourley C; Friedlander M; Vergote IB; Rustin GJS; Fielding A; Spencer S; Parry D; Ledermann JA, 2015, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 8 - 8, http://dx.doi.org/10.1016/j.ygyno.2015.01.015

Banerjee S; Ledermann J; Matulonis U; Molife LR; Friedlander M; Fielding A; Robertson JD; Spencer S; McMurtry E; Kaye S, 2015, 'Management of nausea and vomiting during treatment with the capsule (CAP) and tablet (TAB) formulations of the PARP inhibitor olaparib', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, AUSTRIA, Vienna, pp. S550 - S550, presented at European Cancer Congress, AUSTRIA, Vienna, http://dx.doi.org/10.1016/S0959-8049(16)31525-8

Wuttke M; Milne R; Weideman P; Picken S; Smith C; Friedlander M; McLachlan S-A; Hopper JL; Phillips K-A, 2014, 'Breast cancer screening by women from BRCA1 & BRCA2 mutation positive families', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, presented at 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2014 - 13 December 2014, http://dx.doi.org/10.1158/1538-7445.SABCS14-P3-02-03

Mileshkin L; Sjoquist KM; Sommeijer DW; Cannan D; Martyn J; Gillies K; O'Connell R; Gebski V; Sykes P; Blomfield P; Beale P; Quinn M; Lombard J; Hadley A; Grant P; Antill Y; Stockler M; Amant F; Edmondson RJ; Friedlander M, 2014, 'PARAGON- PHASE II STUDY OF AROMATASE INHIBITORS IN WOMEN WITH POTENTIALLY HORMONE RESPONSIVE RECURRENT/METASTATIC GYNAECOLOGICAL NEOPLASMS: ANZGOG 0903', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 167 - 167, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000345350900278&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML, 2014, 'A new patient-reported outcome measure for symptom benefit with chemotherapy: the Measure of Ovarian Symptoms and Treatment concerns (MOST)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 20 - 20, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lheureux S; Ledermann J; Kaye S; Gourley C; Friedlander M; Bowtell D; De Greve J; DeFazio A; Frommer R; De Bono JS; Audeh MW; Kohn E; Alsop K; Scott C; Matulonis U; Kaufman B; Burger B; Robertson J; Ho T; Oza A, 2014, 'A PILOT INTEGRATED ANALYSIS OF LONG-TERM BENEFIT OF OLAPARIB IN OVARIAN CANCER: RESULTS OF FEASIBILITY TESTING.', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 141 - 142, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500119&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page